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Abstract Bone is commonly affected in cancer. Cancer-
induced bone disease results from the primary disease, or
from therapies against the primary condition, causing bone
fragility. Bone-modifying agents, such as bisphosphonates
and denosumab, are efficacious in preventing and delaying
cancer-related bone disease. With evidence-based care
pathways, guidelines assist physicians in clinical decision-
making. Of the 57 million deaths in 2008 worldwide,
almost two thirds were due to non-communicable diseases,
led by cardiovascular diseases and cancers. Bone is a
commonly affected organ in cancer, and although the inci-
dence of metastatic bone disease is not well defined, it is
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estimated that around half of patients who die from cancer
in the USA each year have bone involvement. Furthermore,
cancer-induced bone disease can result from the primary
disease itself, either due to circulating bone resorbing sub-
stances or metastatic bone disease, such as commonly
occurs with breast, lung and prostate cancer, or from ther-
apies administered to treat the primary condition thus caus-
ing bone loss and fractures. Treatment-induced osteoporosis
may occur in the setting of glucocorticoid therapy or
oestrogen deprivation therapy, chemotherapy-induced ovar-
ian failure and androgen deprivation therapy. Tumour
skeletal-related events include pathologic fractures, spinal
cord compression, surgery and radiotherapy to bone and
may or may not include hypercalcaemia of malignancy
while skeletal complication refers to pain and other symp-
toms. Some evidence demonstrates the efficacy of various
interventions including bone-modifying agents, such as
bisphosphonates and denosumab, in preventing or delaying
cancer-related bone disease. The latter includes treatment of
patients with metastatic skeletal lesions in general, adjuvant
treatment of breast and prostate cancer in particular, and the
prevention of cancer-associated bone disease. This has led
to the development of guidelines by several societies and
working groups to assist physicians in clinical decision
making, providing them with evidence-based care pathways
to prevent skeletal-related events and bone loss. The goal
of this paper is to put forth an IOF position paper address-
ing bone diseases and cancer and summarizing the position
papers of other organizations.
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Epidemiology of cancer-associated bone disease
Bone metastasis
Cancer affects nearly 12.7 million people and is associated with
over 7 million deaths in 2008 [1]. Cancer is a rising global
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health burden and it is estimated that in 2030, cancer deaths will
be tallied at over 13million (WorldHealth Organization (WHO)
2010 Global Status Report [2]). Addressing the morbidity and
mortality of cancer is an important public health concern. On
purpose, we are limiting our analysis to cancer bone involve-
ment in adults and do not discuss cancer in children.
Metastases from cancer are associated with 90 % of cancer
deaths [3]. It was estimated that one half of people who die from
cancer in the USA have bone involvement [4–6]. Different
tumour types may have preferential sites of metastases; how-
ever, the vast majority of tumours metastasize to bone, albeit at
varying frequencies. The term metastatic bone disease reflects
the spread of a tumour to the bone. This term may be applied to
solid tumours, as well as to multiple myeloma, where the
tumour is intrinsic to the bone marrow. In multiple myeloma,
70–95 % of patients have tumour bone disease [7]. In breast
cancer, bone is often the first site of distant metastases [5] with
approximately one half of patients experiencing bone metasta-
ses as the site of first relapse [8]. In advanced breast or prostate
cancer, metastatic bone disease is present in the vast majority of
patients. Bone metastases may also be seen in 15–30 % of
cancers of the lung, gastrointestinal tract (colon and stomach)
and the genitourinary (bladder, kidney and uterus) [9] (Table 1).
In advanced thyroid cancer and melanoma, bone metastases are
also frequently present [7]. Skeletal-related events (SREs) occur
relatively commonly and include pathologic fractures (20.7 %),
spinal cord compression (0.9 %), surgery (1.2 %) and radio-
therapy (8.0 %) to bone and may or may not include
hypercalcaemia of malignancy while skeletal complication also
refers to pain and other symptoms, thus impairing quality of
life, and also decreasing survival [7] and may encompass SREs
as well. New anticancer and supportive care treatment modal-
ities are alleviating symptoms, including bone-related ones, and
maintaining or improving quality of life, at the expense in some
instances of accelerated bone loss and fractures.
Cancer-related bone loss and fracture in patients
who do not have bone metastases
Patients with cancer may be at increased risk of bone loss
secondary to cancer disease treatment [10]. With improved
survival rates in many types of cancer, early identification and
treatment of osteoporosis among cancer patients could prevent
unnecessary fractures, morbidity and reductions in quality of
life. A recent prospective study in Germany of 1,041 cancer
patients, mean age of 57 years, 78 % female, found elevated
rates of osteoporosis compared to the general population [10].
The prevalence of osteoporosis in both men and women with
cancer in complete remission was 16 % (95 % confidence
interval (CI) 13.8–18.2) and osteopenia 44 % (defined using
WHO criteria). Rates of osteoporosis were not statistically
different among various cancer types, which included breast,
gynaecological, prostate, colorectal and haematological can-
cers, although sample size was too small to detect potential
differences in rates between subtypes [10].
Women who have been treated medically for breast cancer
may be at increased risk for bone loss and fractures [11, 12]. In
a case-controlled study of over 1,200 women with newly
diagnosed breast cancer and no metastases, the annual inci-
dence of vertebral fractures was 2.72% compared to 0.53% in
the control arm, i.e. a fivefold increase, with rates adjusted for
age, prevalent fractures and duration of follow-up [12]. Sim-
ilarly, in the prospective observational arm of the Women’s
Health Initiative, fracture rates in breast cancer survivors were
increased by 68.6 fractures per 10,000 person-years, which
compared to rates in women without breast cancer is a 15 %
increase, after adjustment for age, ethnicity, weight and geo-
graphic location [11]. Kanis et al. [12] found a fivefold higher
prevalence of vertebral fractures in women with breast cancer,
but without bone metastases, than in women of the same age
(odds ratio 4.7, 95 % CI 2.3–9.9).
Women with oestrogen receptor positive (ER+) breast can-
cer treated with aromatase inhibitors (AIs) as adjuvant endo-
crine therapy are at increased risk of rapid bone loss, and of
fractures [13–15]. For example in the landmark Arimidex,
Tamoxifen Alone or in Combination (ATAC) trial, average
bone loss rates in women assigned to the AI anastrozole were
1–2 %/year, well above those recorded in women in the
tamoxifen arm [16].
Men with prostate cancer are at particularly high risk of
osteoporosis [17] and of fracture [18] in part due to treatment
with androgen deprivation therapy (ADT). Rates of bone
mineral density (BMD) decrease could be as high as 3.0 to
5.6 %within the first year of ADT, depending on the measured
site, with annual decreases of 1.1 to 2.3 % thereafter [19].
Pathophysiology
Fractures in cancer-associated bone disease can result from the
direct or systemic effect of the tumour itself or from therapies
used to treat the primary disease. In the former case, they are
related to local effects of metastatic deposit in bone and/or to
generalized bone loss from tumour-produced systemically
Table 1 Incidence
of metastatic bone
disease [42]
Incidence (%)
Myeloma 70–95
Breast 65–75
Prostate 65–75 (NCCN, Grawlow)
Renal 20–25
Melanoma 14–45
Thyroid 60
Lung 30–40
Bladder 40
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circulating bone resorbing hormones or cytokines. These
comprise parathyroid hormone-related protein (PTHrP), like
in lung and breast cancer, or tumour stimulated secretion by
the osteoblast of local bone resorbing factors such as receptor
activator of nuclear factor kappa-B ligand (RANKL), inter-
leukin (IL)-6 or IL-3, like in multiple myeloma. Alternative-
ly, bone loss may result from gonadal ablation by chemo-
therapy or endocrine ablative therapy to treat the primary
disease. In some tumours, more than one mechanism may be
operating [20].
Bone metastasis
The bonemicroenvironment represents a fertile soil capable of
favouring the growth of malignant cells coming from a distant
tumour (metastasis) or of haematological origin (myeloma or
lymphoma). Relationships between bone remodelling and
metastatic cells are summarized by the “seed and the soil”
theory proposed in 1879 by Stephan Paget, who noticed that
some cancer cells had an increased propensity to migrate and
expand in bone (cited in [21]). The preferential targeting of the
skeleton by some tumours is in part explained by tumour-
specific factors, and by relevant modulators in the bone mi-
croenvironment, that enhance tumour growth. Indeed, some
particular cancer cells (breast, prostate, malignant lympho-
cytes and plasma cells) possess characteristics that favour their
anchorage in the bone marrow. The pathophysiology of bone
metastasis has been reviewed extensively elsewhere [22–24].
Here, we will summarize the main aspects of the interactions
between malignant cells, bone cells and bone remodelling.
The metastatic cascade
From a primary tumour, malignant cells can acquire the capac-
ity to metastasize due to an increased motility and invasiveness
and a special tropism to bone or bone marrow. They may
produce or express various adhesive molecules for, e.g.
integrins, which can bind to ligand molecules–receptors
expressed by the stromal cells of the bone marrow or to non-
collagenic proteins present in the bone matrix, such as osteo-
pontin. When circulating within the blood stream, cancer cells
can reach the sinusoid capillaries of the bone marrow, which
also contain large pores [25]. Malignant cells can adhere to
these endotheliums and extravase into the bone marrow
environment.
Bone metastases are usually classified as osteolytic,
osteoblastic/osteosclerotic, or mixed (osteolytic and osteo-
blastic), based on their appearance on X-ray images. Many
patients may have both osteolytic and osteosclerotic metasta-
ses, and individual bone lesions can harbour both features.
Predominantly osteolytic metastases are typical of multiple
myeloma, renal cell cancer, thyroid cancer, non-small lung
cancer, some gastro-intestinal tumours, and melanomas.
Predominantly osteosclerotic lesions are most often observed
in prostate cancer, carcinoid, gastrinoma and medulloblasto-
ma. Mixed lesions occur most commonly in breast cancer,
gastrointestinal tumours and most squamous cell cancers at
their primary site. In osteolytic metastases, bone resorption is
due to a stimulation of osteoclastogenesis (and not by a direct
action of the tumour cells), and areas of metaplastic bone at
the margin of the lytic lesions are observed [26] such as in
non-small lung carcinoma, non-Hodgkin’s lymphoma and
thyroid cancer. In osteosclerotic tumours, there is an increase
in osteoclastogenesis but the stimulation of bone formation is
more pronounced.
Development of osteolytic metastasis
Malignant cells release a number of molecules that favour
osteoclastogenesis via the receptor activator of nuclear factor
kappa-B (RANK)/RANKL/osteoprotegerin (OPG) system.
PTHrPmay activate this bone resorption pathway and is detected
by immunohistochemistry in about 90 % of bone metastases
from breast cancer, i.e. more often than in soft tissue metastases
[27]. RANKL has also been shown to trigger the migration to
bone of melanoma and of some epithelial cancer cells that
express the RANK receptor, such as breast cancer cells. In a
mouse model, by blocking RANKL, OPG resulted in a reduc-
tion in tumour burden in bone, but not in other organs [28].
Other bone resorbing factors such IL-1, IL-6, IL-8, IL-11 and
TNF-α have also been identified. Osteoclastogenesis in both
cortical and trabecular bones is increased in the vicinity of the
tumour by a paracrine mechanism. In advanced metastatic
bone disease, hypercalcaemia reflects the release of large
amounts of calcium mobilized due to breakdown of the calci-
fied matrix. During resorption, large amounts of deeply
entrapped growth factors in bone are released and activated
in the microenvironment. Transforming growth factor-beta
(TGF-β), insulin-like growth factor (IGF)-I, and IGF-II pro-
mote the growth of the tumour cells locally through their
receptors, e.g. breast cancer cells express receptors for
TGF-β [24]. αCTX fragments of degraded collagen are also
released from the eroded areas and represent a strong chemo-
attractant for recruiting locally new malignant cells [29].
Development of osteosclerotic metastasis
Prostatic adenocarcinoma is predominantly associated with
osteosclerosis metastases. On histological bone sections, a
large number of osteoblasts building new trabeculae are ob-
served in the vicinity of the tumour cells. The neo-trabeculae
made of woven bone are anchored at the surface of pre-
existing trabeculae and fill the marrow cavity. Prostate adeno-
carcinoma cells are able to release a number of cytokines that
induce osteoclastogenesis including PTHrP. However, malig-
nant cells also express a variety of proteases, e.g. prostate-
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specific antigen (PSA) which partially degrades PTHrP or
IGF-binding proteins, and limit osteoclastogenesis. One char-
acteristic of prostate cancer cells is their production of cyto-
kines that favour osteoblastogenesis: ET-1 [30, 31], IGF-I and
IGF-II, FGF-1 and FGF-2, VEGF. In turn, activated osteo-
blasts can release large amounts of IL-6, TGF-β and PDGF-
BB which are potent growth factors for the tumour cells
[32–34]. In both osteoblastic and osteoclastic metastases, a
vicious circle is established since the malignant cells stimulate
osteoblast or osteoclastic activity, which in turn stimulates
tumour growth and progression.
Bone loss in myelomas and lymphomas
Lytic bone lesions are observed on X-ray in about 95 % of
patients with advanced myeloma, in contrast to what is ob-
served in lymphomas, although both entities are B cells and B-
and T cells malignancies, respectively. Bone involvement is
related to an excessive bone resorption through increased
osteoclast number encountered in the close vicinity of myelo-
ma cells [35] together with a decreased osteoblast activity
[36–38]. In myeloma, the cytokines produced by plasma cells
and bone cell progenitors (IL-6, macrophage inflammatory
protein-1α/CCL-3) induce the genesis of mature multinucle-
ated osteoclasts. In lymphoma, when B cells invade the bone
[39], a mixed population of multi- and mononuclear osteo-
clasts is observed, mononuclear TRAcP+ cells being only
capable of microresorption [40]. Osteolytic lesions are usually
rare in B cell lymphoma (8–10 % of cases) and occur only
when the number of these cells is high [41]. In myelomas and
lymphomas, a marked reduction in osteoblast activity has
been identified by histomorphometric analysis [36]. Plasma
cells can release several factors such as DKK1, sFRP 2, which
act on the Wnt pathway and reduce the osteoblast number and
activity [38]. The lesions observed in myeloma are predomi-
nantly osteolytic and can produce removal of whole trabecu-
lae and perforation of cortical bone.
Cancer-related bone loss and fracture
A variety of mechanisms are responsible for bone loss in
patients with cancer treatment-associated bone loss. The
mechanisms may vary according to patient profile and che-
motherapeutic regimen used. These include hypogonadism
induced by chemotherapy, hormone ablative therapy, gluco-
corticoid, surgical castration, irradiation [42–44] or any com-
bination of the above. Indeed, bone loss has been observed in
lymphoma survivors who received therapy regimens includ-
ing corticosteroids, alkylating agents and radiation therapy, all
of which can cause hypogonadism [45, 46]. The highest rates
for bone loss observed are in premenopausal women who
experience cytotoxic or endocrine-induced acute ovarian ab-
lation, reaching 8 % at the spine and 4 % at the hip, within the
first year [47, 48], compared to half those rates in post-
menopausal women receiving AIs [49–51].
Chemotherapy-induced hypogonadism
Predictors of premature ovarian failure in women with breast
cancer receiving cytotoxic chemotherapy include patient’s age
and type of regimen used. It was reported to occur in 60–85%
of women receiving adjuvant therapy with CMF, and in 50 %
of women receiving the FAC regimens, with age-specific rates
of 33 % in women aged 30–39 years, 96 % for women
between 40 and 49 years and 100 % in women above age 50
[52] (Table 2). Permanent ovarian failure was observed fol-
lowing individual therapeutic doses of various chemotherapy
agents including cyclophosphamide, chlorambucil and
mitomycin-C.
Cyclophosphamide appears to be the most common agent
implicated in chemotherapy-associated amenorrhea. Prema-
ture menopause is dependent on its cumulative dose [52].
Chlorambucil and cyclophosphamide can cause prolonged
azoospermia in male patients [53]. In addition, gonadal toxic-
ity was evident in patients, especially those with testicular
cancer, receiving a cumulative dose of cisplatinum greater
than 400 mg/m2 [54]. Bone loss was also observed in patients
made hypogonadic by cytotoxic drugs used in haematopoietic
stem cell transplantations [55]. In premenopausal women,
tamoxifen treatment is associated with bone loss, through its
antiestrogen effects, whereas it is rather bone protective after
the menopause being a partial oestrogen agonist [56, 57].
Table 2 Cancer treatment regimens directly and indirectly associated
with bone loss [43]
Direct effects Indirect effects
Androgen deprivation therapy Hypogonadism
Oestrogen suppression Hyperparathyroidism
Glucocorticoids/corticosteroids Vitamin D deficiency
Methotrexate Gastrectomy
Megestrol acetate Hyperprolactinemia
Platinium compounds
Cyclophosphamide
Doxorubicin
Interpheron-alpha
Valproic acid
Cyclosporine
Vitamin A
NSAIDS
Estramustine
Ifosfamide
Radiotherapy
Combination chemotherapy regimens
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Hormone deprivation therapy
Osteoporosis stemming from hypogonadism is frequently
seen in survivors of breast and prostate cancer, as therapeutic
hypogonadism is an important strategy for controlling these
hormone-dependent tumours [58].
Aromatase inhibitors
In women with ER+ breast cancers (about 70 % of tumours),
AIs aim to reduce oestrogen levels by inhibiting the aromati-
zation of androgens and their conversion to oestrogens in
peripheral tissues [15]. Third generation non-steroidal
(anastrozole and letrozole) and steroidal (exemestane which
is similar to androstenedione) AI drugs inhibit the aromatase
enzyme by 96–99 % [51], with substantial reduction in
oestrogen concentrations (Table 2). AI-induced bone loss is
generally more rapid and severe than bone loss in normal
postmenopausal women [15], and should be taken into ac-
count especially when treated women with low BMD and/or
fracture [59]. The skeletal effects observed are inversely cor-
related with baseline BMD and serum estradiol concentra-
tions. Osteoporosis is more prevalent in women starting AI
early after menopause, and there is only a partial recovery of
BMD following the withdrawal of AI. Bone loss is accompa-
nied by higher fracture risk [12, 15, 60–63]. This differs
greatly from the effects of tamoxifen or raloxifene given in
the prevention of breast cancer recurrence where increases in
bone turnover may be partially averted and bone loss
prevented. AIs are superior to tamoxifen as adjuvant therapy
of ER+ breast cancer, with longer disease-free survival and
without the risk of endometrial hyperplasia and cancer, cere-
brovascular and venous thromboembolic events, but exhibit
other toxicities such as arthralgias [15, 64]. Recently, AIs have
been shown to further reduce the risk of recurrence after the
diagnosis of ER+ breast cancer, either when given instead of
tamoxifen or when administered sequentially after few years
of tamoxifen therapy, and are thus now recommended in the
adjuvant setting [65]. There is evidence that even the low
levels of oestrogen in postmenopausal women are important
for bone health. In the MORE clinical trial, comparing ralox-
ifene to placebo, there was an inverse correlation between
oestrogen levels and prospectively recorded fracture risk in
those women assigned to the placebo group [66]. Letrozole,
anastrozole and exemestane increase bone turnover [64] and
decrease BMD, and letrozole and anastrozole increase the
relative risk of vertebral and non-vertebral fractures by
40 %, when compared with tamoxifen. After a few years of
AI use, women have a 20–35 % increased fracture risk [67].
For instance, fracture risk has been reported to increase by 55–
115 % with anastrozole in the ATAC [68] and Austrian Breast
& Colorectal Cancer Study Group (ABCSG) [69] trials, by
15–50 % with letrozole in the BIG-198 [70] and MA17 [71]
trials, and by 41 % with exemestane in the IES trial [72], as
compared to tamoxifen or placebo. However, recent data
show that bone loss associated to treatment with aromatase
inhibitors in breast cancer patients is influenced by CYP19
polymorphisms [73].
Sex hormone deprivation therapy with GnRH agonists
and antagonists
Long-acting gonadotropin-releasing hormone (GnRH) ago-
nists with increased receptor affinity or prolonged half-live
lead to persistent activation of gonadotropin-releasing hor-
mone receptors, causing an initial release of pituitary go-
nadotropins followed by a down-regulation of GnRH re-
ceptor and suppression of gonadotropin secretion. Conse-
quently, ovarian sex steroids production is suppressed.
GnRH agonists are effective in the management of endo-
metriosis and of breast cancer in premenopausal women by
suppressing oestrogen levels but they are inducing bone
loss (Table 2). A BMD decrease of about 6 %/year is
observed in patients on GnRH agonists with a recovery
of bone mass after discontinuation. GnRH agonists may not
increase the risk of fragility fractures in women with nor-
mal BMD [43].
In men with hormone-sensitive prostate cancer, castra-
tion or ADT can be induced surgically or medically with
GnRH agonists or antagonists and a combination of GnRH
agonist with androgen biosynthetic blockade. ADT is effec-
tive in reducing tumour extension, growth and improving
survival [74]. ADT can be enhanced by the addition of
androgen biosynthetic blockade such as cyproterone. The
latter two strategies have a different effect on the skeleton.
ADT by either bilateral orchiectomy or GnRH agonist
increases the risk of fractures [18, 75–77]. In contrast,
anti-androgens alone increase rather than decrease BMD
in two randomized trials [78, 79]. Androgen deficiency-
mediated decrease in lean body mass, increase in fat mass
and impaired muscular strength may contribute to increased
fracture risk [80–84] (Table 2). Abiraterone is an inhibitor
of CYP17A1, an enzyme required in androgen synthesis. It
reduces androgen and precursors steroids, and is associated
with a better survival. Abiraterone is administered with
prednisone 5 mg twice daily, or use of another steroid. At
this time, there is insufficient bone data on this treatment
regimen [85].
In men with prostate carcinoma, BMD of hip, ultradistal
radius and lumbar spine decreases by 2–5 % after 12 months
of ADT, and the risk of vertebral and hip fractures increases by
40–50 % [18, 77]. Fracture risk increases linearly with the
number of GnRH injections. It has been estimated that fracture
risk in men on ADT is as high as 20 % by 5 years of treatment
[18, 86]. Older men and those with osteoporosis risk factors in
addition to age are at the highest risk [87].
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Radiation-induced hypogonadism and direct toxic effects
on bone
Both female and male cancer survivors who received irradiation
to the cranium, ovaries or testes can display hypogonadism [88].
The association between male hypogonadism and osteoporo-
sis is further supported by reports of fractures occurring after
external beam radiation therapy to the prostate bed for prostate
cancer [89–92] (Table 2). In addition, pelvic or rib fracture can
occur in relation with bone local irradiation [93, 94].
Glucocorticoids
Themajority of therapeutic regimens for many haematopoietic
malignancies involve high-dose glucocorticoids, usually ad-
ministered over extended periods of time. Glucocorticoids,
which are often used as a pain adjuvant, palliative agent,
antiemetic or as part of the treatment, initially increase bone
resorption, then later suppress osteoblast activity reducing
thereby bone formation [88] (Table 2). Prolonged exposure
to corticosteroids is the third leading cause of osteoporosis,
after hypogonadism and advancing age [95, 96]. The risk of
fracture increases by 50–100 % in recipients of oral cortico-
steroids [97].
Other indirect effects of cancer therapies
There are other indirect effects on bone health that result from
cancer therapies [43]. These effects include hypovitaminosis
D, cachexia (sarcopenia) and decreased mobility (Table 2).
Fracture risk assessment in patients with cancer
and adjuvant therapies
Patients with cancer-associated osteoporosis are generally
younger than patients with postmenopausal osteoporosis. As
people with cancer survive longer, cancer-related skeletal
event and their treatments are becoming increasingly recog-
nized as important co-morbidities [98]. Early evaluation of
risk factors for osteoporosis, including family history of frac-
ture and assessment of peripheral neuropathy that may have
occurred secondary to cancer therapy, medication review,
physical examination, fall risk assessment, diet and exercise
assessment and counselling, as well as changes in BMD over
time, are of prime importance. Fracture risk assessment in this
unique population can be challenging. It should include eval-
uation of BMD and clinical risk factors as detailed below.
Bone mineral density
BMDmeasurement by dual X-ray absorptiometry (DXA) is the
most common clinical tool to directly measure bone mineral
mass and indirectly evaluate bone strength [99]. BMD should
bemeasured byDXA at spine and hip withmeasurements at the
1/3 radius considered if either one of these sites is not available.
Malignancies in bone may either be lytic (e.g. myeloma) or
blastic (e.g. breast or prostate), and if present in the region of
interest, artifact is introduced. Infrequently, DXA images may
give an indication of skeletal metastases requiring other imaging
follow-up. Although radius BMD changes little with osteopo-
rosis therapy, hypogonadism (e.g. from ADT) and hyperpara-
thyroidism often lead to loss of forearm BMD [100]. Several
guidelines recommend that postmenopausal women with breast
cancer on AI, premenopausal women with ovarian failure sec-
ondary to cancer treatment and prostate cancer patients on ADT
should have their BMD measured [42, 101]. For instance, the
American Society of Clinical Oncology (ASCO) recommends
DXA BMD testing in postmenopausal women taking AIs and
premenopausal women who develop treatment-related prema-
ture menopause [102]. The Belgian Bone Club recommends
measuring DXA BMD in all women starting AIs or medical
castration therapy [103]. The UK Expert Group recommends
measuring DXA BMD within 3 to 6 months of commencing
AIs in all women, except for those ≥75 years of age, in whom
treatment decisions are based upon age and clinical risk factor
assessment, independently of BMD [101]. Similarly, an Inter-
national Expert Panel recommends BMD measurement in pa-
tients with breast cancer initiating or receiving AI therapy [104]
as does also the European Society for Clinical and Economical
Aspects of Osteoporosis and Osteoarthritis (ESCEO) [15]. Pa-
tients with bone metastases receiving monthly bone resorption
inhibitors do not require BMD assessment.
Clinical risk factors: 10-year absolute fracture risk
WHO fracture risk assessment tool (FRAX) provides an algo-
rithm applicable for men older than 40 years and for postmen-
opausal women: 10-year fracture risk of the hip and of major
osteoporotic fracture (wrist, proximal humerus, hip and clinical
spine) with and without BMD. Including BMD improves the
predictive performance of the score, that is, improves sensitiv-
ity without decreasing specificity [105, 106]. Although the
FRAX calculator has provided a major advance in our assess-
ment of fracture risk, it does not take into consideration some
other risk factors, due to the nature of the clinical information
available in the cohorts the model was developed from [107].
There is no way of estimating the impact of malignancy or
its treatment from the FRAX algorithm [108], though cancer
treatment-induced bone loss could be considered as second-
ary osteoporosis, the role of which in FRAX fracture assess-
ment is entirely captured by BMD. Clinicians should thus use
their clinical judgement to quantify their patient’s individual
fracture risk.
There are two studies that used the FRAX calculation in
men on ADT. In a cross-sectional study [109], FRAX
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identified more men at risk for fracture than BMD alone. Age
was a very important risk factor. Adler reported [87] that
FRAX derived estimates using femoral neck BMD or calcu-
lated without BMD defined different populations at risk.
Other risk factors
Fall risk, bone turnover markers and many other risk factors
for fracture and bone loss are not included in FRAX. Avariety
of measures of prospective fall risk have been shown to be
useful in predicting fractures. They include questions or
questionnaire-based tools, simple physical performance tests,
measurements of muscle mass and devices that measure some
aspect of strength, balance or integrated function [110, 111].
Bone turnover markers hold promise in fracture risk predic-
tion and for monitoring treatment. However, there are still
uncertainties about their use in clinical practice [112].
Medications
Numerous medications other than glucocorticoids, such as
proton pump inhibitors, can predispose to bone loss (Table 2).
They have not been included in FRAX modelling due to the
infrequency of their use in the general population, their lack of
evaluation in epidemiologic studies and their presumed lesser
effects on bone metabolism.
Prevalent fracture
Prevalent fracture is a powerful predictor for further fractures,
e.g. hip fracture risk is increased by more than twofold by a
prevalent hip or spine fracture, independently of BMD, some of
them being pathologic fractures. Indeed, a spine fracture in-
creases the risk of hip fracture (relative risk (RR)=2.5), subse-
quent spine fracture (RR=4.4), forearm fracture (RR=1.7) or
proximal humerus fracture (RR=1.9) [113, 114]. A greater
number or higher severity of vertebral fracture increases the
risk of vertebral and non-vertebral fracture. However, number,
severity, location of fractures and glucocorticoid dose and
duration are not captured in the current FRAX algorithm
[107, 115]. Pathologic fracture versus osteoporotic fracture
may be difficult to distinguish from plain radiographs and
consideration should be given to other imaging such as com-
puted tomography (CT), magnetic resonance imaging (MRI) or
isotope bone scanning. Asymptomatic vertebral fractures are
very common when appropriate imaging is applied [116].
Concerns for metastatic osseous lesions may be confirmed by
biopsy.
Detection of metastatic cancer to bone
Among the many techniques used for imaging metastases,
each has advantages and limitations [117]. The two “classical”
methods, radiography and scintigraphy, both have limited
sensitivity and specificity. CT and MRI are preferable because
they provide more accurate information [118, 119]. Modern
devices permit scans that cover a large part of the body with
acceptable radiations exposure (for CT) and in reasonable time
(for MRI). While MRI is more suited to detect early infiltra-
tion when the tumour is still restricted to bone marrow and
offers better insight into soft tissue involvement, CT provides
a better characterization of bone integrity. More sophisticated
approaches like positron emission tomography (PET), today
usually used in conjunction with CT (PET/CT), may also be
considered, but the choice of the radiotracer is important. FDG
PET is most commonly used, but the magnitude of the improve-
ment over scintigraphy is controversial [120, 121]. 18F-Fluoride
PET or 18F-choline PET [122] may be better choices but are
more expensive and rarely available. The choice of bone imaging
is impacted by the primary tumour type, the patient’s symptoms
and location of area(s) in question.
Compromised bone integrity may endanger the spinal cord or
other critical structures. Urgent surgical intervention to stabilize
the skeleton and relieve pressure on nerves may be required. For
long bones, lesions that involve 50 % of the diameter of the
cortex or that are larger than 2.5–3 cm are considered at risk for
pathological fracture. Clinical judgment is required to evaluate
all skeletal complications ofmetastatic disease. Particularly at the
spine, the assessment of mechanical stability is complex. New
approaches for evaluation of stability based on CT may be more
accurate, allowing both a better quantification of regional bone
density and specific imaging of bone at high risk of pathologic
fracture. In addition, finite element analysis methods developed
successfully for evaluation of bone strength in osteoporosis [123]
may be adapted in the future to metastatic bone [124, 125].
Prevention and treatment
Prevention of skeletal-related events
Bisphosphonates
Several studies have shown that bisphosphonates have anti-
tumour potentials with direct and indirect effects that result not
only in less bone loss but less tumour burden as well. They
interrupt the vicious cycle in the bone microenvironment
between tumour cells and osteoclasts described in section on
pathophysiology above. Bisphosphonates, in particular zole-
dronic acid, also enhance γδ T cell differentiation (a T lym-
phocyte subpopulation that plays a main role against tumour
cells) and have also potent anti-angiogenic activity in the
adjuvant setting [23]. There is no clear impact of osteoclast
inhibiting therapy on tumour burden. However, two recent
phase III studies suggest that potent osteoclast inhibition may
impact overall survival [126, 127].
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Breast cancer in the adjuvant setting The efficacy of
bisphosphonates in reducing SREs in women with breast
cancer and bone metastatic disease is unequivocal, as demon-
strated in a recent Cochrane meta-analysis [128]. While they
reduce the occurrence of SREs by 15 to 40 % [129], they do
not impact SREs in subjects without bone metastases [130]. In
the frame of adjuvant therapies, evidence from a secondary
endpoint in the Zometa-Femara Adjuvant Therapy Synergy
Trial (ZO-Fast) supports the hypothesis that bisphosphonates
have an anti-metastatic role in breast cancer patients. In more
than 1,000 recruited patients, those in the upfront group had
lower disease recurrence or death than patients in the delayed
group (1.1 vs 2.3 %). No local disease recurrences occurred in
upfront patients while it occurred in 0.6 % of the delayed
group. Efficacy of zoledronic acid was confirmed also in
premenopausal women with a significant improvement in
disease-free survival shown in the ABCSG-12 trial [131]. Both
loco-regional and extraskeletal metastases risk were reduced,
suggesting a systemic anti-tumour effect exerted by zoledronic
acid. The results of these two adjuvant bisphosphonate studies
must be viewed in conjunction with the outcomes of three
other phase III adjuvant bisphosphonates trials. The Adjuvant
Zoledronic Acid to Reduce Recurrence (AZURE) trial ran-
domized 3,360 women with stage II or III early stage breast
cancer to receive standard adjuvant systemic therapy with or
without zoledronic acid. The bisphosphonate dosing was in-
crementally decelerated over the course of 5 years; however,
total dose of zoledronic administered was much greater than
either ZoFast or ABCSG-12. The primary endpoint in AZURE
was disease-free survival. At a median follow-up of 59months,
AZURE demonstrated disease recurrence or death in 377
women in the zoledronic acid group and 375 in the control
group [130]. In subset analysis, postmenopausal women
appeared to have gained benefit from the addition of zoledro-
nic acid. Note that to reach a neutral overall study outcome,
premenopausal women had to have displayer a worse outcome
with the addition of zoledronic acid. There is much speculation
as to account for these findings. In patients with bone metas-
tasis, a retrospective analysis based on 578 patients showed
that zoledronic acid treatment normalized N-terminal
telopeptide (NTX) levels in 81 % of the treated patients within
the third month. Moreover normalization of NTX was associ-
ated with reduced risk of SREs and improved overall survival
[132]. TheNational Surgical Adjuvant Breast andBowel Project
study B-34 [133] randomized 3,323 women to adjuvant
clodronate or placebo with disease-free survival in women with
stage I, II or III breast cancer as primary endpoint. At a median
follow-up of 90.7 months, there were 286 events in the
clodronate group and 312 events in the controls, which was a
non-significant difference (95 % CI 0.78, 1.07; p=0.27). Simi-
larly, in the study GAIN, 3,023 women with lymph node posi-
tive breast cancer were randomized to either oral ibandronate or
placebo. There was equal disease free and overall survival in the
two groups [134]. In another phase III study, patients were
randomized to clodronate, ibandronate or zoledronic acid (with-
out control or placebo arm). The results are due soon [135].
Multiple meta-analyses have been performed using pub-
lished data and came to different conclusions, depending on
the studies selected. It is anticipated that the Early Breast
Cancer Trialist’s Collaborative Group will perform a meta-
analysis based upon raw data and provide thus greater insight
into the situation.
Prostate cancer Earlier studies using pamidronate and
clodronate failed to demonstrate a reduction in SREs in patients
with prostate cancer and bone metastases. In a randomized
controlled trial (RCT) in patients with castration-resistant prostate
cancerwith bonemetastases, zoledronic acid (4mg, 3-weekly) or
placebo reduced SREs (p=0.009) and prolonged the median
time to first SRE from 321 to 488 days (p =0.009) [136].
Bisphosphonates have not been shown to prevent bone metasta-
ses due to prostate cancer in any study. An ongoing study in men
with metastatic prostate cancer compares the early use of zole-
dronic acid (within 3 months of initiation of ADT) to standard
zoledronic acid (on diagnosis of castration resistance). The pri-
mary end point is the proportion of subjects experiencing SREs.
Denosumab
RANKL is a key mediator of metastatic bone resorption.
Denosumab is a human monoclonal antibody that binds and
neutralizes human RANKL. It prevents RANKL from acti-
vating RANK on osteoclasts, inhibiting osteoclast formation,
function and survival, and hence reducing bone resorption.
Therefore, RANKL inhibition through denosumab is a thera-
peutic target for preventing and treating bone metastases.
Breast cancer In a study evaluating the efficacy of denosumab
in 2,046 breast cancer patients with bone metastases in a
double-blind double-dummy trial, denosumab (120 mg
monthly) was superior to zoledronic acid (4 mg monthly with
adaptation of the dose to the renal function) in suppressing
bone turnover and delaying or preventing SREs. Denosumab
increased the time to first on-study SRE by 18 % compared
with zoledronic acid (hazard ration (HR), 0.82; p <0.001 for
non-inferiority and p =0.01 for superiority). The median time
to first on-study SRE was 26.4 months for the zoledronic acid
group and had not been reached for the denosumab treatment
group. Denosumab also delayed the time to first and subse-
quent (multiple) on-study SREs by 23 % compared with
zoledronic acid (multiple event analysis; p =0.001). The mean
skeletal morbidity rate (defined as the ratio of the number of
SREs per patient divided by the patient’s time at risk) was also
lower with denosumab than with zoledronic acid (0.45 vs 0.58
events per patient per year; p =0.004), which represents a
reduction of 22 % with denosumab. Overall survival and
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disease progression were similar in the two treatment groups.
Safety profile, including onset of osteonecrosis of the jaw, was
similar between both groups [137].
Prostate cancer In a study comparing denosumab (120 mg
monthly) to zoledronic acid (4mgmonthly) for the prevention
of SREs in 1,904 men with castration-resistant prostate cancer
metastatic to bone, the primary end point was the time to first
SRE. Denosumab proved to be non-inferior (p =0.0002) and
superior (p =0.008) compared to zoledronic acid. Denosumab
delayed the time to first on-study SRE by 18% compared with
zoledronic acid (HR, 0.82) and the median time to first on-
study SRE was 3.6 months longer with denosumab compared
with zoledronic acid. Denosumab also significantly delayed
the time to first and subsequent on-study SREs by 18 %
compared with zoledronic acid (p =0.008). Overall survival
and disease progression evaluated by changes in PSA levels
did not differ between both groups [138].
In the adjuvant setting, when denosumab 120 mg every
4 weeks was compared to placebo in preventing bone metas-
tases in 1,432 men with castration-resistant prostate cancer and
at high risk of developing bone metastases, bone metastasis-
free survival was higher (p =0.028) and time to first bone
metastasis increased (p =0.032) in the denosumab group.
Denosumab improved bone metastasis-free survival by a me-
dian of 4.2 months compared with placebo (29.5 vs
25.2 months; HR, 0.85; p =0.028). Time to symptomatic bone
metastasis was also prolonged. Overall survival was similar in
both groups, but studymedications were stoppedwhen the first
bone metastasis was diagnosed. Denosumab was associated
with higher incidence of hypocalcaemia (1.7 vs 0.3 %) and
osteonecrosis of the jaw (4.6 vs 0 % at the end of year 3) [139].
Other solid tumours and multiple myeloma In a third study
with an identical design, 1,776 patients with multiple myelo-
ma or bone metastases and solid tumours (except those of
prostate or breast) were randomized to receive denosumab or
zoledronic acid. Approximately 40 % of patients in the study
had non-small cell lung cancer and 10 % multiple myeloma.
Denosumab was non-inferior to zoledronic acid in delaying
the time to first on-study SRE (HR, 0.84; p =0.0007), but,
after adjustment for multiple comparisons, the difference be-
tween the groups was not statistically significant for treatment
superiority (p =0.06). The median time to first on-study SRE
was 20.6 months for denosumab and 16.3 months for zole-
dronic acid. Overall survival and disease progression were
similar in both treatment groups [140].
Integrated analysis of the three phase III trials in metastatic
patients
The identical design of the three phase III studies conducted in
patients with metastatic bone disease allowed for a pre-
planned integrated analysis of the data involving a total of
more than 5,700 patients. Denosumab increased the time to
first on-study SRE by 17 % over zoledronic acid (HR, 0.83;
95 % CI, 0.76–0.90; p <0.001 for superiority). The median
time to first SRE was 27.7 months with denosumab and
19.4 months with zoledronic acid. This integrated analysis
showed that denosumab delayed the time to first and subse-
quent on-study SREs by 18 % compared with zoledronic acid
(HR, 0.82; 95 % CI, 0.75–0.89; p <0.001 for superiority).
Overall survival and disease progression were similar with
both treatments [132]. The integrated analysis showed that the
cumulative incidence of confirmed osteonecrosis of the jaw
(ONJ) after 3 years was not negligible (n =89 from total of 5,
723 patients; 1.6 %) with no significant difference between
denosumab and zoledronic acid treatments (1.8 vs 1.3 %; p =
0.13) [141]. The role of denosumab in the management of
hypercalcaemia of malignancy has not yet been evaluated and
clinical trials should be conducted to more clearly document
this effect.
Conclusion for the prevention of skeletal-related events
in breast cancer
In a recent meta-analysis of 34 RCTs conducted in women
with various stages of breast cancer, Wong et al. have
demonstrated the unequivocal efficacy of bone resorption
inhibitors in reducing the incidence of SREs in women
with bone metastatic disease [128]. Bisphosphonates re-
duced the risk of SREs by 15 % (RR=0.85, 95 % CI,
0.77–0.94), in nine studies of 2,806 women with bone
metastases. This benefit was observed with intravenous
(IV) zoledronic acid (4 mg/3–4 weeks) with RR 0.59
(95 % CI, 0.42–0.82), IV pamidronate (90 mg/3–4 weeks)
(RR=0.77; 95 % CI, 0.69–0.87) and IV ibandronate (RR=
0.80; 95 % CI, 0.67–0.96), with one direct comparison in
a large study confirming the equivalent efficacy of
zoledronate and pamidronate. In three studies comprising
3,405 patients with skeletal metastases, denosumab was
superior to a bisphosphonate in reducing the risk of SREs
(RR=0.78; 95 % CI, 0.72–0.85) [128]. Such therapies did
not influence the outcomes of women without bone me-
tastases at study entry. The authors also concluded that
there is insufficient evidence to make a conclusion about
the role of adjuvant bisphosphonates in reducing visceral
metastases, loco-regional recurrence and total recurrence or
improving survival. Toxicity was generally mild kidney
toxicity and ONJ were reported at similar rates for patients
on denosumab compared to zoledronic acid.
Prevention of bone loss and fractures
As in idiopathic osteoporosis, preventivemeasures to maintain
bone health include lifestyle changes, adequate calcium and
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vitamin D, regular physical exercise and pharmacotherapy
such as bisphosphonates, denosumab or selective oestrogen
receptor modulators (SERMs).
Lifestyle, calcium and vitamin D
Lifestyle interventions are crucial in order to improve quality
of life and maximize any pharmacological treatment in cancer
patients. The American Cancer Society, the World Cancer
Research Fund/American Institute for Cancer Research and
the American College of Sports Medicine have released
guidelines for cancer survivors [142–144], recommending at
least 30 min daily of physical activity for at least 5 days per
week. Exercise interventions are also beneficial for muscle
strength and bone mass, reducing also the risk of falls and, in
turn, potentially of hip fractures.
Patients with malignancies are exposed to risk factors that
may predispose to vitamin D deficiency. Among them, inade-
quate sunlight exposure, poor dietary intakes and treatment
with medications that reduce vitamin D absorption are the most
common [145, 146]. Indeed, 76–88 % of breast cancer survi-
vors have low vitamin D levels, i.e. <20 ng/mL [147–149]. A
recent study has shown that low vitamin D levels are highly
prevalent among newly diagnosed breast cancer patients with
nearly 44 % with vitamin D insufficiency [150]. As expected,
African-Americans are more affected than Caucasians [150].
Clinical trials using vitamin D in cancer patients are lacking. In
a recent double-blind placebo-controlled randomized phase II
trial, breast cancer patients on AIs, treated with vitamin D2, had
less aromatase inhibitor-induced musculoskeletal symptoms
than those on placebo. Vitamin D-treated patients had also a
stable BMD at the femoral neck (0.45 %±0.72), compared to a
1.39 % decrease seen in the placebo group [151]. The ASCO
recommends supplementation with calcium and vitamin D in
breast cancer patients, mostly if treated with AIs [102]. How-
ever, routine 25-hydroxyvitamin D measurement is not part of
the current guidelines in breast cancer patients. Given the lack
of clinical trials, no guidelines on specific levels of supplemen-
tation for vitamin D or calcium are available. Vitamin D
supplementation should be given in order to bring serum 25-
hydroxyvitamin D levels to 20 ng/mL (50 nmol/L) or higher
[152]. According to data obtained in postmenopausal women, a
daily intake of at least 800 IU should be advised together with a
daily calcium intake (from food and supplements) of 1,000 mg.
The intake of calcium from the diet should be favoured because
it has been suggested that high doses of calcium supplements
were associated with increased cardiovascular risks [153]. The-
se recommendations have been extended from National Com-
prehensive Cancer Network (NCCN) Bone Health in Cancer
Care Task Force to premenopausal women at risk of cancer
treatment-associated bone loss.
As advised by the NCCN Prostate Cancer Guidelines
(available at www.nccn.org), similar preventive measures,
with calcium and vitamin D supplementation, should be
applied to patients with prostate cancer, particularly if on
ADT. A sufficient intake of calcium and vitamin D should
be emphasized in those on intravenous bisphosphonates or
denosumab to avoid the risk of hypocalcaemia.
Bisphosphonates
Bisphosphonates have been successfully used in patients with
metastatic bone diseases to reduce SREs [154]. However, their
use has been extended to prevent bone loss in patients with
both breast or prostate cancer in the adjuvant setting, who are
treated with chemotherapy or hormonal therapy [131]. This
approach is in accordance with the wide use of bisphosphonates
in idiopathic osteoporosis [155].
Breast cancer In premenopausal women with breast cancer,
adjuvant chemotherapy induces early menopause, a strong
factor of accelerated bone loss. Few trials have evaluated the
efficacy of bisphosphonates to attenuate chemotherapy-
induced bone loss in young women [156–164]. The adminis-
tration of oral clodronate at daily doses of 1,600 mg, oral
risedronate at a dose of 30 mg/day, cyclical intravenous
pamidronate at doses of 60 mg every 3 months and intrave-
nous zoledronic acid at a dose of 4 mg every 3 months
prevented chemotherapy-induced bone loss in these studies.
Numerous other studies have confirmed such findings and are
summarized in Table 3.
Bisphosphonates have also been shown to prevent AI-
induced bone loss. The SABRE trial has tested in an open
label approach the effect of risedronate in breast cancer pa-
tients on anastrozole. At 24 months follow-up, medium-risk
patients on risedronate had a significant increase in lumbar
spine and total hip BMD compared with anastrozole and
placebo (2.2 vs −1.8 and 1.8 vs −1.1 %, respectively). In the
high-risk group, lumbar spine and total hip BMD increased
(3.0 and 2.0 %) while those on anastrozole had a 2.1 %
decrease [165]. In the ARIBON study, early stage breast
cancer patients receiving anastrozole were treated with
ibandronate (high risk), ibandronate or placebo (medium risk),
or anastrozole only (low risk). At 24 months, ibandronate-
treated patients (150 mg orally every month), compared to
placebo, had a higher BMD and suppressed markers of bone
turnover [166]. Overall, these data confirm that oral
bisphosphonates improve BMD and may normalize bone turn-
over in AI-treated patients.
Prevention of AI-induced bone loss has been tested also
using intravenous infusions of zoledronic acid. The Z-Fast
and ZO-Fast were designed to compare effects of zoledronic
acid (4 mg intravenously) initiated either with letrozole and
every 6 months thereafter (upfront group) or given only when
bone loss became significant or a fragility fracture occurred
(delayed group) [147]. In over 1,667 patients, the upfront
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regimen significantly improved lumbar spine BMD (+5.2 %)
and total hip BMD (+3.5 %) versus the delayed group. N-
telopeptide and ALP dropped by 21.3 and 12.8 % in the
upfront group and increased by 21.7 and 24.9 % in the
delayed group. No differences were found between the two
groups in terms of fractures, although the study was not
designed to test this endpoint. Disease recurrence was less
frequent in the upfront group and no case of osteonecrosis of
the jaw was reported. Encouraging data were also obtained in
premenopausal women in the ABCSG where zoledronic acid
prevented bone loss in a subgroup of premenopausal cancer
patients [50]. These and other studies are presented in
Table 3.
Prostate cancer Alendronate, risedronate, zoledronic acid,
denosumab and teriparatide are approved for the
treatment/prevention of osteoporotic fractures in men with
osteoporosis with some limitations according to regional
policies. The use of teriparatide is not recommended in
cancer-treated patients. Available RCTs in the setting of
ADT and prostate cancer have shown efficacy in the pre-
vention of bone loss, a significant increase in BMD and
normalization of bone turnover in the dosages normally
recommended for idiopathic osteoporosis [167, 168].
Pamidronate (60 mg IV 12-weekly) in a small prospective
study in men with non-metastatic prostate cancer signifi-
cantly increased BMD at the spine and hip [83]. Zoledronic
acid (4 mg IV as single dose) in a RCT of ADT and non-
metastatic prostate cancer significantly increased BMD at
spine and hip, when compared to placebo [169]. There is
presently no published trial of the effect of a bisphospho-
nate on fracture risk in the ADT/prostate cancer setting.
These and other studies are presented in Table 5.
Denosumab
Breast cancer The efficacy of denosumab was evaluated in
252 patients receiving adjuvant AI in the HALT-BC trial.
Patients randomly received either placebo or denosumab
(60 mg) every 6 months. In the denosumab group, BMD in
all examined skeletal sites was increased already after 1 month
of treatment, and at 12 and 24months was significantly higher
than placebo [170, 171]. At 24months, the difference between
both treatment groups was 7.6 % at the lumbar spine and
4.7 % at the total hip. At the lumbar spine, BMD increased
by more than 3 % in 80 % of denosumab-treated patients
compared with 10 % in the placebo group. An increase in
BMD with denosumab was observed at lumbar spine after
1 year (+5.5 %) and at radius after 2 years (+6.1 %). No
serious adverse events were attributed to denosumab in the
trial. An ongoing clinical trial is investigating the anti-fracture
efficacy of denosumab in women with breast cancer receiving
AI in an adjuvant setting [172].Ta
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Prostate cancer In the HALT Prostate trial, 1,468 men receiv-
ing ADT for prostate cancer and being at high risk for fracture
(history of osteoporotic fracture, age ≥70 years or low BMD)
were randomized to either denosumab (60 mg subcutaneously
6-monthly) or placebo for 3 years. At 2 years, BMD of the
lumbar spine (the primary endpoint) increased by 5.6 % in the
denosumab group as compared with a decrease of 1.0 % in the
placebo group (p <0.001). Denosumab increased BMD at
various skeletal sites (femoral neck, total hip, distal radius)
and reduced the 3-year incidence of new vertebral fractures by
62 % (1.5 vs 3.9 % in the placebo group; HR, 0.38; 95 % CI,
0.19–0.78; p =0.006), fractures at any site by 72 % (p =0.10)
and multiple fractures at any site by 72 % (p =0.006). In a
further post hoc analysis, a trend was found toward a positive
effect on non-vertebral fractures [173].
Selective oestrogen receptor modulators
In a RCT of 646 men with prostate cancer and ADT, subjects
randomly received the SERM toremifene (80 mg oral daily) or
placebo for 2 years. Toremifene significantly reduced the risk
of new vertebral fractures by 50 % (p =0.05), increased BMD
at the spine and hip, and decreased markers of bone turnover
[174]. Raloxifene improved BMD at the hip and tended to
improve BMD at the spine in another small open-label study,
but has not been studied with fracture endpoints [175].
Official recommendations and comparison of guidelines
Metastatic bone disease
Tables 3 (breast), 4 (multiple myeloma) and 5 (prostate) summa-
rize the various national and international recommendations for
the management of bone disease in cancer patients and the
suggested approaches to bone assessment and follow-up. The
2003 recommendations from the ASCO for the prevention and
treatment SREs in patients with metastatic breast cancer [102]
were updated in 2011 [154] (Table 3). The 2011 differ from the
2003 ones in the addition of denosumab to intravenous
bisphosphonates. Bone-modifying agent therapy is only recom-
mended for patients with breast cancer with evidence of bone
metastases; denosumab 120 mg subcutaneously every 4 weeks,
intravenous pamidronate 90 mg over no less than 2 h or zole-
dronic acid 4 mg over no less than 15 min every 3 to 4 weeks is
recommended. ASCO also issued clinical practice guidelines to
manage lytic bone disease or compression fractures in patients
with multiple myeloma with intravenous bisphosphonates [176,
177]. IV zoledronic acid or pamidronate is recommended for
preventing SREs in patients with multiple myeloma. Zoledronic
acid is preferred over oral clodronate in newly diagnosed patients
with multiple myeloma because of its potential anti-myeloma
effects and survival benefits. Bisphosphonates should be
administered every 3 to 4 weeks IV during initial therapy.
Zoledronic acid or pamidronate should be continued in patients
with active disease and should be resumed after disease relapse,
if discontinued in patients achieving complete or very good
partial response (Table 4).
Although several studies suggest the potential usefulness of
bone-modifying agents in preventing extension in other pa-
renchymas, including skeletal metastases, in patients without
metastatic bone disease at study entry, the evidence is not
conclusive. The Cancer Care Ontario group has also issued
recommendations to use zoledronic acid in adult patients with
renal carcinoma and bone metastases [133].
Treatment-induced bone loss
The ASCOGuidelines Update committee on adjuvant endocrine
therapy for women with ER+ breast cancer recommends that
postmenopausal women with hormone receptor-positive breast
cancer consider incorporating an aromatase inhibitor therapy at
some point during adjuvant treatment, either as upfront therapy
or as sequential treatment after tamoxifen. The optimal timing
and duration of aromatase inhibition remain unresolved. The
ASCO panel supports careful consideration of side effect profiles
and patient preferences in deciding whether and when to incor-
porate AI therapy (Table 3). Risk stratification based on BMDT-
score and clinical risk factors has been the recommended ap-
proach by several organizations to identify patients who most
benefit from inhibitors of bone resorption. The issue of use of
bone-modifying agents in the management of adjuvant-
associated bone loss in patients with breast cancer is to be
covered by ASCO in a separate guideline update that is eagerly
awaited [154, 178].
General recommendations
Cancer without known skeletal metastases and not requiring
therapy to lower sex steroid
Risk assessment should be applied as in non-cancer patients
[179–182]. A detailed history and a focused physical examination
are recommended to identify risk factors for low BMD, falls and
fractures, as well as undiagnosed vertebral fractures. Hip and spine
BMD should be measured with DXA according to the local
guidelines for DXA use in non-cancer patients. FRAX should be
calculated using femoral neck BMD and pharmacotherapy intro-
duced according to guidelines for non-cancer patients.
For postmenopausal women or men over age 50 with
densitometric osteoporosis (T-score ≤ −2.5 at the total hip,
femoral neck or lumbar spine) or prevalent fragility fracture,
laboratory investigations to rule out secondary causes of bone
loss are recommended (blood cell count, calcium, phosphate,
alkaline phosphatase, TSH, 25-hydroxyvitamin D, creatinine,
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serum protein electrophoresis) as in idiopathic osteoporosis.
The use of bone turnover markers to improve fracture risk
assessment or to monitor therapy remains controversial. How-
ever, in patients with skeletal metastatic disease, elevated
markers of bone resorption appear to be associated with
poorer prognosis and increased mortality [183].
Lateral thoracic and lumbar spine radiography, or VFA by
DXA, if clinical evidence is suggestive of a vertebral fracture,
should be performed. Vertebral fractures are defined as defor-
mities of vertebrae with reduction greater than 20 % of verte-
bral dimension. Thirty percent of vertebral fractures are
asymptomatic and therefore imaging in patients at risk should
be encouraged. Such fractures are highly predictive of future
fracture and have a marked influence on FRAX outcome.
Non-metastatic cancer treated with endocrine therapy
All of the above can be applied to this group of patients. Women
who are taking AI and men who are undergoing ADTshould be
assessed for fracture risk, and osteoporosis therapy to prevent
fractures should be considered (Figs. 1 and 2).
Follow-up
Baseline status, osteoporosis and bone fracture risk factors,
and the type of cancer therapy used influence the frequency,
profile and duration of examinations included in the follow-up
of these patients [76, 101, 104].
Most of the cancer treatment-induced bone loss is
explained by the hypogonadal state induced by the therapies.
Thus, the follow-up currently focusses on the measurement of
BMD and perhaps of bone turnover markers (BTMs) [101].
The goal of therapy is the maintenance (with some agents) or
the increase (with other agents) in BMD. BTMs may respond
with increases, with some therapies and decreases with other
therapies. Measuring BMD or BTMs may increase adherence
to therapy in individual patients.
A general approach and practical algorithm is presented in
Figs. 1 and 2, which also emphasize the important role played
by osteoporosis risk factors in the follow-up and management
of these patients. Other organizations such as ESCEO, ASCO
and the UK Expert Group have also issued other algorithms
that are also anchored on BMD T-scores cut-offs and risk
factors [15, 101, 102]. Indications and limitations can be
region-specific according to the approval or insurance reim-
bursement policies.
Breast cancer
BTMsmay be used tomonitor response to antiresorptive therapy.
The most commonly used specific markers are serum cross-
linked terminal telopeptide (CTX) on a serum sample collected
between 7 and 10 h in the morning in fasting state and urinary
NTX expressed as a ratio to creatinine andmeasured on a second
morning void urine sample. With the use of bisphosphonates as
antiresorptive therapy, a 50–70 % reduction of CTX and NTX is
expected in the first 3 months of treatment, a plateau is observed
thereafter. It is generally accepted that the goal is to reduce bone
resorption by more than the least significant change, keeping the
bone resorptionmarkers into the lower half of the reference range
for healthy young women [101, 184]. Currently, a reduction in
Initial Assessment: DXA, FRAX, Ca, PTH, 25-OHD, (BTM)
Premenopausal with 
Ovarian Suppression
- T-Score < - 1.0
- ≥ 1 Vertebral Fr.
- Prevalent Fragility 
Fr.
Postmenopausal
- T-Score < - 2.5
- T-Score < - 1.5 & ≥ 1 CRF
- T-Score < - 1.0 & ≥ 2 CRF
- FRAX ≥ 3 % for Hip Fr.
Postmenopausal
- Prevalent Fragility Fr.
- Age ≥ 75 Yrs
General Measures: regular physical activity 
vitamin D ≥ 800 IU/day or 10’000 IU/week 
calcium intake ≥ 1000 mg/day
smoking cessation
Antiresorptive Therapy: - Zoledronic Acid 
(AI Treatment Duration) - Oral bisphosphonates (compliance!)
- Denosumab 
Women Starting Aromatase Inhibitor for Breast CancerFig. 1 Management of patients
with breast cancer treated with
aromatase inhibitors (AIs).
Adapted from [15]
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bone resorption greater than 50 % indicates that the least signif-
icant change has been achieved. It has been shown that concom-
itant diseases and recent fractures can influence BTM levels, thus
caution needs to be taken when interpreting the results [185].
BMD value and the number of risk factors of each individ-
ual patient should be known before the initiation of any kind
of bone-sparing therapy in all cancer treatment-associated
bone loss (Figs. 1 and 2). Conversely, as the increases in
BMD on treatment are small, BMD should be measured
preferably at lumbar spine where the least significant change
is around 3%. BMD should be measured every 18–24months
[101, 186] in patients treated with bone resorption inhibitors.
Elderly women (>65 years) and patients with T-score <
−2.0 and at least one more additional risk factor should receive
bone protection with bisphosphonates irrespective of BMD if
they are receiving AI therapy (Fig. 1).
Different management [101] is proposed in cancer therapy-
induced premature menopause compared with biologically
occurring menopause. In treatment-induced menopause or in
programmed ovarian suppression before the age of 45 years,
the evaluation of BMD should be indicated in two sites (spine
and hip) and BMD should be repeated 12 months [187] after
post-chemotherapy amenorrhea occurrence. The frequency of
further monitoring would depend on the baseline BMD and
the type of treatment. When AIs are concomitantly used,
monitoring (every 18–24 months) and therapeutic intervention
with calcium, vitamin D supplements and bisphosphonates are
recommended [101].
Patients with a T-score between −1 and −2 should be
considered “medium risk”. However, patients with medium
risk with a decline of BMD >4 % per year (either site) should
initiate bone protection therapy. Finally if BMD is ≥1, the 10-
year risk for osteoporosis is very low and only lifestyle mea-
sures should be prescribed with re-evaluation in 24 months.
Prostate cancer
Bisphosphonates have been shown to attenuate bone loss, but
optimal regimen (IV vs oral route of administration, every
6 months vs every 12 months) and the long-term effect on
fracture risk remain to be established. Therefore, there is a
need for bone monitoring measuring BMD with DXA.
Denosumab has also been shown to increase bone mass in
ADT patients who are at high risk of fracture and decrease
BTMs. BMD and BTMs should be followed during
treatment [84].
The frequency of monitoring will depend on the baseline
DXA, the presence of osteoporosis risk factors and the use of
bisphosphonates. Differently to breast cancer, high, medium
and low-risk groups have been clearly established in prostate
cancer, but a similar approach to breast cancer for monitoring
is currently adopted [188].
If T-score is ≤ −2.5 patients should be monitored and man-
aged as high-risk patients. If T-score is between −1 and −2.5, a
more frequent monitoring (12 months) is advised. Patients with
a T-score ≥ −1 can be considered at lower risk and BMD studies
Men Starting Androgen Deprivation Therapy for Prostate Cancer
T-Score ≤ -2.5
FRAX > 20% (major fracture) 
FRAX at the hip > 3%
T-Score ≤ -1.0 and > -2.5
FRAX < 20%
•
•
•
Pharmacological interventions
Zoledronic acid
Oral bisphosphonates (compliance!) 
Denosumab
Thoracolumbar spine X-ray  
General Measures: regular physical activity 
vitamin D ≥ 800 IU/day or 10’000 IU/week 
calcium intake ≥ 1000 mg/day
smoking cessation
Initial Assessment: DXA, FRAX, Ca, PTH, 25-OHD, (BTM)
Fig. 2 Management of patients
with non-metastatic prostate
cancer on androgen deprivation
therapy (ADT)
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repeated every 18–24 months [101, 186]. If bisphosphonates
are used in the frame of ADT, BMD should be measured every
18 to 24 months (Fig. 2).
Conclusions
Bone is often affected in the course of cancer either as bone
metastases or as bone loss and fragility resulting from anti-
cancer therapies. These various disease complications are
associated with an important morbidity and with a largely
compromised quality of life. To preserve bone and reduce this
morbidity, efficacious therapies are available, with a highly
favourable risk–benefits ratio. Expert reports from various
societies are providing guidance for the identification of pa-
tients at risk of bone disease, their management and follow-up.
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